Biocytogen Launches “Nano 100 Project” to Develop Fully Human Nanobody Therapeutics for Over 100 Targets
21.2.2023 17:11:00 EET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced the launch of the “Nano 100 Project”, which aims to develop fully human nanobody drugs for over 100 targets. The Project combines Biocytogen’s proprietary fully human nanobody mouse, RenNano®, with its high-throughput in vitro and in vivo antibody screening platforms to develop fully human nanobody drugs on a large-scale.
Compared to traditional antibodies, nanobodies have smaller molecular weights and improved tissue penetration ability, which make them effective at infiltrating tumors and crossing blood-brain barriers. Additionally, nanobodies generally have longer CDR3 regions which enables them to recognize hidden epitopes better. Due to their simpler structure, nanobodies are more stable and easier to produce and engineer, making them ideal building blocks for complex modalities such as cell therapy, bispecific antibody and engager, multi-specific antibody, antibody drug-conjugate (ADC), and radionuclide antibody-conjugate (RAC).
After several years of endeavor, Biocytogen successfully engineered the RenNano mouse from its fully human antibody mouse, RenMab™. RenNano mouse possesses full human heavy chain variable regions and can produce heavy-chain-only antibodies (HCAbs). The variable regions of HCAbs, i.e., nanobodies, do not require in vitro humanization to develop drugs. Our research has shown that RenNano mouse can generate robust immune responses after immunizations by different antigens. HCAbs generated from the RenNano mouse have highly diverse CDR3 sequences and can recognize many epitopes with nM-level high affinities. In vitro and in vivo experiments have shown that RenNano-derived antibodies have favorable biological functions.
Based on RenNano’s excellent ability to discover fully human nanobodies, Biocytogen has launched the “Nano 100 Project”. The Project aims to develop fully human therapeutic nanobodies against over 100 targets, including tumor associated antigens (TAAs), GPCRs, immune-checkpoints, cytokines, and factors related to neurological diseases. Biocytogen is actively seeking collaborations with global pharmaceutical and biotech companies to combine its large-scale nanobody development abilities with collaborators’ expertise in nanobody-related therapeutics, such as cell therapies, bispecific and multi-specific antibodies, ADCs and RACs, to develop novel drugs with first-in-class and/or best-in-class potentials.
“We believe that with the ability to rapidly develop fully human nanobodies against selected targets, the ‘Nano 100 Project’ will provide our global partners with more diverse and better nanobody building blocks to accelerate the development of novel drugs,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Meanwhile, it is also an important supplement to Biocytogen’s Project Integrum.”
About RenNano®
Biocytogen's proprietary fully human nanobody generating mouse, RenNano, is one of the most comprehensive fully human antibody platforms in the world. Nanobody sequences generated from RenNano mice have the highest possible diversity and do not require antibody humanization, which saves time and cost and reduces the risk of failure during later stages of drug development. Additionally, compared to natural HCAb-producing species like camelids, mice are easier to breed and immunize, making them suitable for developing HCAbs on a large scale.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal antibody, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005554/en/
Contact information
Biocytogen
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SES Advances Next-generation MEO Strategy Following Successful Completion of IRIS² Rendez-vous 17.8.2026 11:52:00 EEST | Press release
SES today announced the successful completion of Rendez-vous 1 (RDV1) under the Infrastructure for Resilience, Interconnectivity and Security by Satellite (IRIS²) programme, marking a key milestone in the programme's implementation phase and reinforcing Europe's path towards sovereign, resilient and secure satellite connectivity. The successful completion of RDV1 confirms the programme's readiness to move forward with implementation and provides greater visibility on the long-term scope, performance and economics of the MEO segment. SES's expected capital commitment for the MEO segment is up to €1.35 billion, reflecting current programme scope, while maintaining the deployment of 18 MEO satellites and the targeted service entry in 2030. SES’s share of the investment in the IRIS² programme for 2026 is included in SES’s FY26 Capex outlook as previously communicated. No future exceptional cash proceeds will be used to fund the project. Since the signing of the IRIS² Concession Contract in
Allianz Delivers Record Result and Is Well on Track to Achieve Its Targets7.8.2026 08:10:00 EEST | Press release
2Q 2026 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806509750/en/ Oliver Bäte, Chief Executive Officer of Allianz SE Total business volume at 45.6 billion euros, an internal growth of 5.7 percent1, with contributions from all segments. Asset Management delivers excellent growth. Operating profit rises 10.6 percent to a record level of 4.9 billion euros. Shareholders’ core net income at 2.6 billion euros; 12.7 percent below last year. Adjusted for a divestment gain last year and offsetting measures following the sale of the stake in our Indian JVs, underlying growth is strong at 10 percent. 6M 2026 Total business volume at 98.6 billion euros, an internal growth of 4.3 percent1, driven by Property-Casualty and especially Asset Management. Operating profit rises 8.6 percent and reaches a record level of 9.4 billion euros. Shareholders’ core net income advances 15.5 percent to 6.4 billion euros. Adjusted for divestment eff
Pure Lithium Receives Australian Patent for "Lithium Metal Anode and Battery"6.8.2026 23:49:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated next-generation lithium metal battery technology company, today announced that the Australian patent office has granted the company a patent (AU2025271196) titled “Lithium metal anode and battery.” Australia mines roughly half of the world’s lithium, yet has no domestic battery production at all; every battery the country uses is imported. The granted patent is directed to ways in which Pure Lithium’s technology can change that. Rather than trying to catch up in lithium-ion, Australia can leapfrog the incumbent technology and establish a next-generation industry. As worldwide demand for batteries grows, every country capable of making batteries needs to be making them. That is Pure Lithium’s central goal: opening up markets around the world through battery technology that enables local, independent supply chains, keeping pace with demand and strengthening economies. China controls the lithium-ion battery supply chain and manufactures th
Vercel Appoints Amit Agarwal, Standard Template Labs CEO and former Datadog President, to Board of Directors6.8.2026 18:00:00 EEST | Press release
Vercel, the agentic infrastructure company, today announced the appointment of Amit Agarwal, former president of Datadog and founder and CEO of Standard Template Labs, an AI-first service management platform, to its board of directors. Agarwal brings 25 years of enterprise software experience and a track record of scaling a product-led company from its earliest days into one of the defining public software companies of the cloud era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806738617/en/ Amit Agarwal Agarwal joined Datadog in 2012 as its Chief Product Officer and was named President in 2022, overseeing product, corporate development, and go-to-market functions as the company grew past $2.5 billion in annual revenue. Across 13 years, including Datadog's 2019 IPO and its first years as a public company, Agarwal helped build one of the industry's most studied examples of product-led growth at enterprise scale. He conti
Laserfiche Launches Advanced Enterprise Security to Deliver Multi-Region Disaster Recovery and GovRAMP-Ready Compliance for Highly Regulated Industries6.8.2026 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management — today announced the launch of Enterprise Security, an advanced suite of security enhancements designed for organizations navigating complex regulatory environments. Enterprise Security addresses GovRAMP and CJIS (Criminal Justice Information Services) security requirements based on the NIST SP 800-53 framework. For organizations handling privileged citizen, legal or corporate data, these built-in controls streamline audit preparation and fortify defenses. With organizations placing a higher priority on data stewardship and corporate governance, enterprise IT leaders require a security architecture that protects data without slowing down operations. Laserfiche Enterprise Security extends Laserfiche Cloud’s highly resilient infrastructure with multi-region data replication, elevated security controls for privileged accounts, and built-in governance safeguards. “Maintaining data integrity and compliance has always
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom